Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.

@article{Gridelli2011GefitinibAF,
  title={Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.},
  author={Cesare Gridelli and F. De Marinis and Massimo Di Maio and Diego Luigi Cortinovis and Federico Cappuzzo and Tony C. W. Mok},
  journal={Lung cancer},
  year={2011},
  volume={72 1},
  pages={3-8}
}
Randomized trials comparing gefitinib with chemotherapy as first-line treatment in patients with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment option in this setting. However, its use in clinical practice has several relevant implications and open issues. In order to choose the best treatment, a molecular characterization is now mandatory, as part of baseline diagnostic procedures. Every effort should be made in order to obtain sufficient tissue. If a… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

PET/CT-guided percutaneous biopsy of FDG-avid metastatic bone lesions in patients with advanced lung cancer: a safe and effective technique

European Journal of Nuclear Medicine and Molecular Imaging • 2016
View 6 Excerpts
Highly Influenced

Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…